Grifols Q3 revenue exceeds estimates as immunoglobulin sales drive growth

Grifols reported Q3 revenue of €2.04 billion, up 8.4% at constant currency and above the €1.98 billion consensus; net profit rose 27.9% to €162 million and adjusted EBITDA increased 9.8% to €538 million. Biopharma revenue grew 10.3%, while albumin revenue fell 13.2%; the company confirmed full-year guidance and reported €208 million of free cash flow before M&A, with net leverage down to 3.98x from 4.2x a year earlier. U.S.-listed shares rose 5% Monday but fell 1.4% in Tuesday premarket trading, while Madrid-listed shares were down 1.1%.

Analysis

The quarter supports a deleveraging-and-execution thesis, but not yet a clean rerating: reported free cash flow is before M&A and may be sensitive to working capital, while leverage near 4x leaves limited tolerance for missed operating targets. The 2027 refinancing lowers near-term liquidity risk; it does not remove the balance-sheet discount, with the next material maturity window still ahead. The market’s partial giveback after the initial rally suggests investors may be looking for sustained cash conversion rather than another revenue beat.

Near term, SPARTA topline results are the clearest event risk; without the study details and outcome, treat this as binary rather than underwriting a positive read-through. Over 1–3 months, track whether albumin weakness in China reverses as inventories normalize and regulatory factors ease. If it persists, strong immunoglobulin growth may not translate into the expected consolidated improvement. Over 6–18 months, Egypt’s planned plasma collection expansion could support supply and growth, but targets are not proof of productive capacity; collection execution, economics and regulatory progress need verification. Increased industry plasma capacity could also intensify competition for donors and pressure collection economics across the sector, including CSL and Takeda.

Contrarian angle: the growth mix is encouraging, but investors may be over-weighting headline revenue and under-weighting cash-flow quality and the time required to reduce leverage. Conversely, continued cash generation could make the refinancing milestone more valuable than the muted premarket reaction implies.

Key Decisions for Investors

• Avoid chasing the post-results rally. Consider a small, staged long in GRFS only if subsequent reporting confirms positive free cash flow after working-capital movements and continued leverage reduction; no price target is supportable from the supplied data.
• Treat SPARTA as an event-risk hold rather than a directional catalyst trade until the study design, endpoint and topline are verified. Reassess on the actual result; do not assume a favorable outcome.
• Monitor the next quarter for China albumin inventory/regulatory normalization, cash conversion excluding M&A, and net leverage. Persistent albumin weakness or a reversal in cash generation would falsify the improving-balance-sheet thesis; sustained cash generation and lower leverage would strengthen it.
• Watch Egypt’s actual collection volumes and economics against the stated ramp before capitalizing the 2029 goal. If execution lags, reduce the value assigned to future supply growth and reassess whether donor-plasma constraints could benefit competitors such as CSL or Takeda.